ImmunoMark Summit
UK — London 2026
Decoding the Next Wave of IO Biomarkers
Inside ImmunoMark Summit — London 2026
Two days. Two streams. Over 400 scientists, executives, and innovators at the DoubleTree by Hilton, Tower of London. Here's what it looked like.
Who Were In the Room
ImmunoMark Summit London 2026 attracted a deliberately senior, cross-functional audience — the decision-makers, scientists, and innovators actively shaping the future of immuno-oncology and precision diagnostics across Europe and beyond.
Audience by Sector
Seniority Breakdown
Attendee Domains
Geography
60% UK & Ireland · 40% Rest of Europe
Post-Show Report — London 2026
The inaugural European edition of ImmunoMark Summit concluded on 6th March 2026 — and the results exceeded every benchmark we set. Here is what the data and feedback told us.
By the Numbers
Senior Professionals
Attended across both days from pharma, biotech, academia, and beyond
Expert Speakers
Presented across both parallel streams over two full days
Sponsors & Partners
Supported the event across Platinum, Gold, and Silver tiers
Parallel Streams
Next-Gen IO and Biomarkers & CDx — running simultaneously all day
Exclusive Gala Dinner
End of Day 1 networking reception and dinner at the Tower of London venue
Would Recommend
Post-event survey respondents said they would recommend ImmunoMark Summit
Scientific Highlights
Next-Gen Immuno-Oncology
Opened with a landmark keynote from Louis Boon (JJP Biologics). Sessions covered CAR-T multi-antigen targeting for solid tumours, Treg cell modulation in glioblastoma, ML-driven multispecific antibody engineering, patient-derived tumour models with AI spatial profiling, molecular mimicry for cancer vaccine design, and NK cell therapy in CLL and lymphoma.
Biomarkers & CDx
Keynote by John Smeraglia (AstraZeneca) on biomarker strategy as a clinical decision-making tool. Sessions on home-sampling biomarkers, extracellular vesicle profiling, AI-driven PD-L1 standardisation, and a landmark panel — Biomarkers as Market-Makers in Oncology — moderated by Yariv Hefez (Merck), with panellists from J&J and Roche.
Full Post-Show Report
Comprehensive post-event analysis, attendance data, and session highlights in PDF format.
Summit Highlights Reel
ImmunoMark Summit London 2026 — Highlights Reel
TESTIMONIALS
What Sponsors Said
Don't take our word for it. Here's what the scientists, executives and innovators who attended ImmunoMark Summit London 2026 had to say.
We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.
We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.
Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.
My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.
We got the occasion to discuss customer projects and understand their needs better and how we can help them.
The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.
Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.
The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.
